Evaluation of the Humoral Immune Response of a Heterologous Vaccination between BBIBP-CorV and BNT162b2 with a Temporal Separation of 7 Months, in Peruvian Healthcare Workers with and without a History of SARS-CoV-2 Infection.
Evaluation of the Humoral Immune Response of a Heterologous Vaccination between BBIBP-CorV and BNT162b2 with a Temporal Separation of 7 Months, in Peruvian Healthcare Workers with and without a History of SARS-CoV-2 Infection.
复制标题
DOI：
10.3390/vaccines10040502
复制
发表时间：
2022-03-24
期刊：
影响因子：
7.8
通讯作者：
Rodriguez-Morales, Alfonso J.
中科院分区：
文献类型：
--
作者：
Hueda-Zavaleta, Miguel;Gomez de la Torre, Juan C.;Alonso Caceres-Del Aguila, Jose;Muro-Rojo, Cecilia;De la Cruz-Escurra, Nathalia;Arenas Siles, Daniella;Minchon-Vizconde, Diana;Copaja-Corzo, Cesar;Bardales-Silva, Fabrizzio;Benites-Zapata, Vicente A.;Rodriguez-Morales, Alfonso J.
关键词：
关于首次接种BBIBP-CorV疫苗的成人患者中异源加强剂的作用的信息有限。这项前瞻性队列研究评价了来自利马（秘鲁）一家私人实验室的152名医务工作者（HCW）在接种BNT 162 b2疫苗前后的体液应答，BBIBP-CorV接种后间隔7个月。我们采用Elecsys®抗SARS-CoV-2 S和cPass™ SARS-CoV-2中和抗体（NAb）测定法分别评估抗S-RBD IgG和NAb。在152名HCW中，79名（51.98%）既往感染过（PI）SARS-CoV-2，73名（48.02%）既往未感染（NPI）。免疫后7个月，NPI组和PI组NAb阳性率分别为49.31%和92.40%。在加强注射后，这一比例在两组中都增加到100%。医务人员NPI中抗S-RBD IgG和NAb分别增加了32.7倍和3.95倍。在HCW的PI中，这一增量分别为5倍和1.42倍。既往SARS-CoV-2感染史与加强免疫后抗S-RBD IgG和NAb滴度之间无统计学相关性。体液免疫在接受BNT 162 b2加强剂后呈现出稳健的增加，并且在NPI中更明显。
Information on the effects of a heterologous booster in adult patients first vaccinated with the BBIBP-CorV vaccine is limited. This prospective cohort study evaluated the humoral response of 152 healthcare workers (HCWs) from a private laboratory in Lima (Peru) before and after receiving the BNT162b2 vaccine, with a seven-month interval since the BBIBP-CorV doses. We employed the Elecsys® anti-SARS-CoV-2 S and the cPass™ SARS-CoV-2 Neutralization Antibody (NAbs) assays to evaluate anti-S-RBD IgG and NAbs, respectively. Of the 152 HCWs, 79 (51.98%) were previously infected (PI) with SARS-CoV-2 and 73 (48.02%) were not previously infected (NPI). The proportion of HCWs with positive NAbs, seven months after the BBIBP-CorV immunization, was 49.31% in NPI and 92.40% in PI. After the booster, this ratio increased to 100% in both groups. The anti-S-RBD IgG and NAbs in the HCWs’ NPI increased by 32.7 and 3.95 times more, respectively. In HCWs’ PI, this increment was 5 and 1.42 times more, respectively. There was no statistical association between the history of previous SARS-CoV-2 infection and the titer of anti-S-RBD IgG and NAbs after the booster. The humoral immunity presented a robust increase after receiving the BNT162b2 booster and was more pronounced in NPI.
登录
查看更多内容
影响因子：
5.5
作者：
Moghnieh R;Mekdashi R;El-Hassan S;Abdallah D;Jisr T;Bader M;Jizi I;Sayegh MH;Rahman Bizri A
通讯作者：
Rahman Bizri A
DOI：
10.1056/nejmoa2119451
发表时间：
2022-04-21
期刊：
The New England journal of medicine
影响因子：
--
作者：
Andrews N;Stowe J;Kirsebom F;Toffa S;Rickeard T;Gallagher E;Gower C;Kall M;Groves N;O'Connell AM;Simons D;Blomquist PB;Zaidi A;Nash S;Iwani Binti Abdul Aziz N;Thelwall S;Dabrera G;Myers R;Amirthalingam G;Gharbia S;Barrett JC;Elson R;Ladhani SN;Ferguson N;Zambon M;Campbell CNJ;Brown K;Hopkins S;Chand M;Ramsay M;Lopez Bernal J
通讯作者：
Lopez Bernal J
影响因子：
5.6
作者：
Vályi-Nagy I;Matula Z;Gönczi M;Tasnády S;Bekő G;Réti M;Ajzner É;Uher F
通讯作者：
Uher F
DOI：
10.1056/nejmoa2110345
发表时间：
2021-11-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Thomas SJ;Moreira ED Jr;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Polack FP;Zerbini C;Bailey R;Swanson KA;Xu X;Roychoudhury S;Koury K;Bouguermouh S;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Yang Q;Liberator P;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Gruber WC;Jansen KU;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
DOI：
10.1056/nejmoa2109072
发表时间：
2021-10-14
期刊：
The New England journal of medicine
影响因子：
--
作者：
Bergwerk M;Gonen T;Lustig Y;Amit S;Lipsitch M;Cohen C;Mandelboim M;Levin EG;Rubin C;Indenbaum V;Tal I;Zavitan M;Zuckerman N;Bar-Chaim A;Kreiss Y;Regev-Yochay G
通讯作者：
Regev-Yochay G